spacer
home > ebr > spring 2017 > pinpointing the problem
PUBLICATIONS
European Biopharmaceutical Review

Pinpointing the Problem

EBR: Biomarkers are fast becoming an essential part of drug discovery and development. How did we get here and what advantages do they bring?

Dr Mario L Rocci Jr: A biomarker is a tool we use to assess a bodily process or function. This can define what is abnormal or characteristic when a disease is present, and how this improves after the disease is ameliorated through some form of therapeutic treatment. For instance, biomarkers can involve the measurement of a specific substance in a blood, urine or tissue sample, or might be scans resulting from imaging evaluations.

So there are several ways that they can best be used in drug discovery and development. Efficacy biomarkers can be utilised as an indicator of whether a drug being manufactured is likely to be efficacious in improving disease. Good examples include the use of serum glucose measurements or the ability to reduce HbA1C levels when developing drugs to treat diabetes, and the use of serum cholesterol and low-density lipoprotein levels when creating therapies for atherosclerotic disease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mario L Rocci Jr, a Senior Vice President at ICON Laboratories, has authored over 150 publications including a book on regulated bioanalysis due out in 2017. He is a past president of the American Society for Clinical Pharmacology and Therapeutics and the American Association of Pharmaceutical Scientists (AAPS), where he received the AAPS Distinguished Service Award. Mario is a member of an External Advisory Board at the University of Kentucky, US, a fellow of the American College of Clinical Pharmacology, US, and a fellow and past Board member of the International Pharmaceutical Federation.
spacer
Dr Mario L Rocci Jr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

World-leading cancer stem cell expert joins Avacta Scientific Advisory Board

Developer of biotherapeutics and research reagents announces the appointment of Professor Gerard Evan to its Scientific Advisory Board
More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

 
Industry Events

DIA 2017 Annual Meeting

18-22 June 2017, Chicago, IL

Themed “Driving Insights to Action,” DIA 2017 will host 8,000+ professionals in the pharmaceutical, biotechnology, and medical device communities from more than 50 countries. DIA 2017 boasts more than 450 exhibiting companies, 10+ tracks, and 160+ sessions focused on regulatory science, translational medicine, patient engagement, and value and access. Follow DIA 2017 updates on Twitter using #DIA2017.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement